Introduction {#S1}
============

The current worldwide incidence of dementia is believed to be fifty million people, and this number is expected to reach 75 million in 2030 if no cure is found (Alzheimer's disease international, 2017) \[[@R1]\]. Alzheimer's disease, the most common form of dementia, is characterised by neuropathological changes (including the development of β-amyloid plaques (Aβ), Neurofibrillary Tangles (NFTs) and other anatomical features that spread throughout the brain) that result in a variety of clinical symptoms including short-term and long-term memory loss, confusion, depression and language problems. Ultimately, patients can become severely demented, lose ambulation and are reduced to a behavioural repertoire consisting of a few basic reflexes \[[@R2],[@R3]\]. The individual neuropathological features of the AD brain are not unique to this disease, and are found across a spectrum of disorders and species \[[@R4]\]. One such example is Down Syndrome (DS), where individuals develop Aβ neuritic plaques, tau-containing NFTs \[[@R5]\], Basal Forebrain Cholinergic Neurodegeneration (BFCN) and enlarged early endosomes. These features may be the result of an over-expression of multiple genes or an alteration in key proteins or discrete cellular pathways. It has also been suggested, however, that another shared pathology, enlarged early endosomes, may contribute to pathological processes in both AD and DS and may be mediated through common pathways. Two genes involved in endocytosis, both located on chromosome 21, are intersectin-1 (ITSN1) and the regulator of calcineurin-1 (RCAN1, formerly called Down syndrome candidate region 1) \[[@R6]--[@R9]\]. This is relevant because DS is characterised by a triplication of chromosome 21, which is also the location of the Amyloid Precursor Protein (APP) gene that ultimately gives rise to the Aβ protein that forms the plaques found in AD and DS.

Through endocytosis, neurons achieve the rapid vesicle recycling necessary for maintaining neurotransmission but endocytosis is also the process used by neurons and other cell types to take up macromolecules from the extracellular environment. Early endosomes receive extracellular molecules from the cell surface via fusion with clathrin-coated vesicles. Disrupted endocytosis has been postulated to result in abnormal uptake and trafficking through signalling endosomes of vital plasma membrane proteins, growth factors and receptors \[[@R10]\]. Early endosomes are the sites of internalisation of APP and apolipoprotein E, as well as the site of Aβ peptide generation, all of which contribute to the manifestation of AD \[[@R11]\]. In addition, defective neuronal growth factor signaling due to disturbances in endocytosis could be an early event in the manifestation of AD \[[@R12]\] which can lead to the formation of amyloid plaques, hyperphosphorylated tau and NFTs and BFCN \[[@R13]\]. In DS, enlarged endosomes are seen as early as 28 weeks of gestation in neurons \[[@R10]\], which precedes diffuse Aβ plaque deposition which appears at around 12 years of age, and is followed by mature Aβ plaques when the individuals are in their 30s \[[@R14]\]. In 2008 the genes associated with cognitive decline in the brains of aging individuals with AD were identified by profiling RNA expression of the whole genome in the frontal cortex and comparing them to their matched controls. Of relevance to this study, amongst the RNA transcripts significantly up-regulated in AD was the short isoform of intersectin-1 (ITSN1-S) \[[@R15]\]. Although this study reported that ITSN1 is overexpressed in the AD brain \[[@R15]\], there is nothing in the literature about the expression of ITSN1 at the protein level or in other types of dementia. It is of note, however, that ITSN1 protein levels have been examined in DS individuals that had concomitant AD pathology \[[@R16]\]. This study showed that DS individuals with AD pathology have a higher level of expression of ITSN1 in their frontal cortex compared with healthy controls, but interestingly DS individuals with diagnosis of AD had lower levels of both ITSN1-S and -L compared to DS without an AD diagnosis \[[@R16]\]. Similarly, previous studies have shown that the level of RCAN1 mRNA was increased in the AD brain \[[@R17],[@R18]\] and that the level of RCAN1 protein was increased in the pyramidal neurons of the AD temporal lobe \[[@R19]\], but there is almost nothing in the literature about the levels of RCAN1 in other types of dementia. Ermak et al. \[[@R17]\] also showed that amyloid β1--42 stimulates production of RCAN1 mRNA in a cell culture model. Furthermore, Lloret et al. \[[@R20]\] showed that in a primary rat neuronal cell culture model in the presence of amyloid β, tau phosphorylation increased but silencing RCAN1 in these neurons blocked the hyperphosphorylation of tau indicating that RCAN1 has a role in tau phosphorylation.

For these reasons, we hypothesised that protein levels of both ITSN1 and regulator of calcineurin-1 RCAN1 would be altered in AD brain tissues, and may also be altered in related conditions, including Dementia with Lewy bodies (DLB) and non-Alzheimer's disease dementia (non-AD; including corticobasal degeneration and supranuclear palsy). Changes in these proteins may implicate endocytic and lysosomal trafficking deficits across a broad suite of neurodegenerative diseases.

As our targets of interest have been found in various tissues throughout the body \[[@R21]\], we were also interested in determining whether or not they were changed in the periphery, as this might represent a potential biomarker \[[@R22],[@R23]\] or provide some insight into the pathogenesis of disease. For these analyses we were fortunate to have access to white blood cells, which are a critical component of the peripheral compartment and may be involved either directly or indirectly in the pathogenesis of a variety of conditions including AD \[[@R24],[@R25]\], from both healthy controls and AD patients from the Australian imaging, Biomarker and Lifestyle Study of Ageing (AIBL). Furthermore, both ITSN1 and RCAN1 are involved in transporting material inside and outside the cell; RCAN1 regulates vesicle exocytosis \[[@R26]\] and ITSN1-L isoform regulates the amount of secretory vesicle exocytosis and synaptic vesicle endocytosis \[[@R9]\]. Therefore, it is possible that they would be involved in the transportation of metals, which are reported to be involved in the pathogenesis of a variety of neurodegenerative diseases (such as AD). ITSN1 is also involved in receptor-mediated endocytosis, and it is reported to impact the internalization of the transferrin receptor, which is crucially involved in cellular iron regulation \[[@R27]\]. Hence, we hypothesised that if the level of ITSN1 and RCAN1 were altered in the periphery, then this may also translate to a change in metal levels. Hence, we assessed both protein (ITSN1 and RCAN1) and metal (including major elements such as copper, zinc, iron and calcium) content in the white blood cells.

Materials and Methods {#S2}
=====================

Human brain tissue {#S3}
------------------

Human post-mortem brain tissues used in this project were provided by the Victorian Brain Bank Network and the University of California Alzheimer's Disease Research Center (UCI-ADRC) and the Institute for Memory Impairments and Neurological Disorders. The demographics of these cases are listed in [Table 1](#T1){ref-type="table"}. Samples included frontal and temporal cortices from controls with no neurological disorders (average ± SD; 80.8 ± 14.5 years of age), AD (78.3 ± 9.1 years of age), non-AD (including corticobasal degeneration and progressive supranuclear palsy cases; 77.7 ± 6.9 years of age), and DLB (82.6 ± 7.3 years of age) patients. There was no statistical difference in the average age of each of these cohorts. The average Post Mortem Interval (PMI) for the tissues were as follows; controls (22.1 ± 27.7 hours), AD (33.4 ± 22 hours), non-AD (28.6 ± 16.3 hours) and DLB (41.8 ± 22.7 hours). The variation in PMI is similarly large across all the groups, and there was no statistically significant difference between groups. The tissues were stored at −80°C until required.

Human blood samples {#S4}
-------------------

White blood cell samples from fasting AD (n=50, 77.5±11.5 years of age) and age-matched healthy controls (n=20, 79 ± 10 years of age) were obtained from AIBL.

Western blotting of human samples {#S5}
---------------------------------

Western blotting was used to quantify the relative levels of RCAN1, ITSN1 long and ITSN1 short isoforms in both human brain and white blood cell samples. Specific cohort sizes are shown in the figures. Post-mortem tissue was weighed and homogenized in 4× the volume in Phosphate Buffered Saline (PBS) containing 0.1% SDS and 0.1% Triton-100, supplemented with proteinase inhibitor tablets (Roche) and phosphatase inhibitors (Roche, Mannheim, Germany). White blood cell samples were homogenised in dH~2~O containing 0.1% SDS and 0.1% Triton-100, supplemented with proteinase inhibitor tablets (Roche) and phosphatase inhibitors (Roche, Mannheim,Germany). Each sample was sonicated for 10 cycles of 10 seconds on and 10 seconds off. Further, the samples were spun for 10 mins and the soluble phase collected for experiment. Protein concentrations of all the samples were initially quantified using a bicinchoninic (BCA) protein assay kit (Pierce, Thermo scientific, Rockford, USA) so that equal protein concentrations (40 μg) of each homogenised sample could be loaded per lane and subsequently resolved on 3--8% Criterion XT Tris-Acetate pre-cast gels (Bio-Rad, Hercules, CA, USA) using XT Tricine running buffer (Bio-Rad, Hercules, CA, USA). This was followed by electroblotting onto polyvinylidene fluoride (PVDF) membranes (Immobilon-P) using transfer buffer containing 5% methanol.

Membranes were incubated in milk (5%w/v) followed by applying the primary rabbit anti-ITSNl (1:750) (Abcam, Cambridge, UK) in blocking buffer (5% w/v fat-free milk in TBS containing 0.1% Tween-20, pH 8.0) and anti RCAN-1 (1:1000; MorphoSys AG, Planegg, Germany) in signal boost solution 1 buffer (Calbiochem, Darmstadt, Germany) and incubated overnight at 4°C.

Immunoreactive proteins were detected using HRP-conjugated rabbit anti-mouse (1:2000; Dako, Glostrup, Denmark) in blocking buffer (5% w/v fat-free milk in TBS containing 0.1% Tween-20, pH 8.0) or HRP-conjugated goat anti human (1:2000, Jackson ImmunoResearch Laboratories, West Baltimore, USA) in signal boost solution buffer 2, respectively. ITSN1 membranes were incubated with Amersham ECL western blotting detection reagent and RCAN1 was visualized using Luminata Forte western HRP substrate (Millipore, Burlington, USA). Images of the western blots were taken using an ImageReader LAS-3000 (FujiFilm, Tokyo, Japan) and the abundance of proteins quantified (density of bands at the given molecular weight) using ImageQuant software (GE Healthcare, Fairfield, USA). The data are then presented as relative band intensity.

Metal analysis by inductively coupled plasma mass spectrometry {#S6}
--------------------------------------------------------------

Due to our long standing interest in the role of metals in the pathogenesis of AD, we assessed metal levels in the white blood cells from both AD and healthy control patients. Whilst this in of itself is interesting, to determine whether there was any potential involvement of ITSN1 and RCAN1 in metal homeostasis in the periphery (which may reflect central metal changes), then we correlated the protein and metal levels. We utilized Inductively Coupled Plasma Mass Spectrometry (ICPMS) as described previously \[[@R28]\]. Triplicates of each sample were measured.

Statistical analysis {#S7}
--------------------

Data for human tissue are presented as box and whiskers for comparison of AD and controls, and were compared using a two-tailed student's t-test. Unless otherwise stated, data are presented as means ± SEM for other types of dementia and controls, and were compared by one way ANOVA with Dunnet's post-hoc test. Data for WBCs metals were analysed using a two-tailed student's t-test. A Pearson's two-tailed correlation test was used to test the correlation between proteins and metals. All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). On all the figures, the significance is denoted by the following: \*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001.

Results {#S8}
=======

Intersectin-1 protein levels are unchanged in brain tissue in various neurological diseases {#S9}
-------------------------------------------------------------------------------------------

There were no differences between the levels of ITSN1 proteins in frontal and temporal cortices of AD patients compared with the controls (unpaired two-tailed t-test; n=6--10 for control frontal cortex and n=6--12 for AD frontal cortex; n =8--10 control temporal cortex, n=11--22 for AD temporal cortex ([Figure 1a](#F1){ref-type="fig"}--[1d](#F1){ref-type="fig"}). Similarly, there were no differences between other types of dementia and the controls (one way ANOVA with Dunnet's post-hoc test; [Figure 2a](#F2){ref-type="fig"} and [Figure 2b](#F2){ref-type="fig"}).

RCAN1 levels are elevated in the temporal cortex in AD and DLB {#S10}
--------------------------------------------------------------

Assessment of RCAN1 levels in frontal and temporal cortices from our cohort of neurological diseases ([Figure 1e](#F1){ref-type="fig"}, [Figure 1f](#F1){ref-type="fig"} and [Figure 2c](#F2){ref-type="fig"}) revealed a significant elevation only in the temporal cortex of both AD and DLB tissue, as compared to controls ([Figure 1f](#F1){ref-type="fig"} and [Figure 2c](#F2){ref-type="fig"}). There were no other differences noted.

Intersectin-1 and RCAN1 protein levels in white blood cells in AD {#S11}
-----------------------------------------------------------------

The protein levels of both the short and long isoforms ofITSN1 ([Figure 3a](#F3){ref-type="fig"} and [Figure 3b](#F3){ref-type="fig"}), as well as RCAN1 ([Figure 3c](#F3){ref-type="fig"}) were no different between the AD and healthy controls.

Metal analysis in white blood cells, and correlation with RCAN1 and ITSN1 {#S12}
-------------------------------------------------------------------------

There were no differences in the levels of any metals measured (iron, zinc, copper, calcium, magnesium, manganese, aluminium, lead or selenium) between the AD and the control white blood cells ([Table 2](#T2){ref-type="table"}). We also examined whether there was a correlation between the level of the proteins of interest (RCAN1 or ITSN1) and the level of each metal across our two cohorts using a Pearson's two-tailed correlation. There was no correlation between the levels of any of the proteins and metals ([Table 2](#T2){ref-type="table"}).

Discussion {#S13}
==========

This study has demonstrated that there are elevated levels of RCAN1 protein in both AD and DLB temporal cortices, as compared to matched controls. These findings are consistent with a previous study conducted in AD patients, where it was shown that RCAN1 mRNA was elevated (\~ two fold) in the cerebral cortex (areas A10 and A22) and hippocampus, but not the cerebellum, of AD patients \[[@R17]\]. This study also demonstrated an association with NFTs, such that RCAN1 mRNA was significantly higher in patients with extensive NFTs (\~ three fold). In a cell culture system, it was also shown that amyloid β1--42 increases RCAN1 mRNA \[[@R17]\]. This current study, therefore, extends on the previous work that only examined changes in RCAN1 mRNA, to demonstrate that this is likely to also translate to protein level changes in AD. That RCAN1 was also altered in DLB may speak to converging pathways in DLB and AD. Studies such as Lippa et al. \[[@R29]\] have also shown the presence of Lewy bodies in many Down syndrome brains with AD. Further studies are required to investigate the relevance of RCAN1 in AD, and to also interrogate the potential role/interaction of RCAN1 in the context of neurological diseases such as DLB. We did not observe any differences in RCAN1 levels in WBCs of AD and healthy controls, which may suggest that changes in the level of RCAN1 in the post-mortem brain might be locally/differently regulated compared with peripheral RCAN1 levels. As with the post-mortem brain studies, further work is required to understand how changes in RCAN1 levels in the AD brain may contribute to the disease evolution and progression. Although our results did not show a significant change in the levels of ITSN1 in the AD brain or the other types of dementia, statistical power analysis revealed that if the number of samples was increased to 35 or more per group, the result might reach statistical significance (this would also potentially help overcome issues around varying PMI times and the limited "snapshot" that comes from analysing individuals from an isolated age range). That our current data are in conflict with an existing report suggesting that ITSN1 levels are elevated in AD, this previous study assessed RNA levels only, whereas we assessed protein levels in the current body of work. As such, it is possible that there is disconnect between the RNA and protein regulation/levels for ITSN1, or perhaps there was a cohort-specific difference between studies that would account for this difference. One consideration is the PMI, which could impact protein measurements. A few minutes after death, autolysis occurs resulting in the release of water and enzymes which degrade proteins, carbohydrates and lipids \[[@R30]\]. Environmental factors such as temperature and humidity would also affect the rate of decomposition. For this reason, it is hard to predict how the PMI by itself has affected the protein content of the samples \[[@R16]\]. Similarly, it is not possible to predict in what way our data for levels of ITSN1 protein in dementia brains would have been affected. Nevertheless, the samples with the longer PMI times would likely have had more protein decomposition than the samples with the shorter PMI, which could have affected the level of ITSN1 measured in the samples (whilst there were no significant differences in the PMI between cohorts in the current study, there was a trend for the healthy control group to have shorter PMI times than all other groups). Obtaining better controlled autopsy samples would help mitigate some of these issues. Another issue to consider is whether the presence of significant systemic disease in our sample population might have influenced the outcomes of the current studies, as there were individuals that had sepsis and renal failure amongst other comorbidities \[[@R31]\]. Given the reported role of ITSN1 in a breadth of cellular pathways, then this remains an important caveat of our work.

Conclusion {#S14}
==========

There is a potential point of intersection between the neuropathology/disease pathogenesis present in DS and other neurological diseases such as AD and DLB that centers around the regulation of RCAN1 and potentially the associated endocytic pathways. Further investigation is required to understand the relevance of this protein and pathways to disease.
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![Levels of ITSN1 and RCAN1 proteins in frontal and temporal cortices of AD patients.\
Western blotting was performed on homogenates of human post-mortem brains (n=6-- 11 frontal cortex (FCX), n=11--22 temporal cortex (TCX)) and age-matched controls (C; n=6-- 10 FCX, n=8--10 TCX). Plots (a, b, c, d) show levels (densitometry) of ITSN1-S and L in post- mortem brains of AD patients compared with age-matched controls e) There is no difference between the AD and control in levels of RCAN1 frontal cortex. f) The level of RCAN1 protein is significantly higher in the AD temporal cortex compared with the control. Representative blots are shown. The box and whisker graphs show median, minimum and maximum values. An unpaired two-tailed t-test was used for statistical analysis (p=0.022). \*p\<0.05.](nihms-1034718-f0001){#F1}

![ITSN1 and RCAN1 protein levels in different types of dementia.\
There were no differences in the level of ITSN1 in different types of dementia compared with the controls (a,b)\[(for frontal cortex (FCX): n=10 for control (C), n=8 for non-AD, n=3 for DLB; and for temporal cortex (TCX): n=10 for control, n=11 for non-AD, n=6 for DLB\]. However, the level of RCAN1 is elevated in DLB temporal cortex compared with control (c) (for frontal cortex: n=9 control and n=8 for non-AD (due to tissue limitations and technical difficulties, we only had an n=1 for the frontal cortex from DLB patients, and so left this out of the analysis); for temporal cortex: n=10 control, n= 6 for non-AD, n= 3 for DLB; p= 0.011 for DLB). The representative blots of ITSN1 and RCAN1 protein levels in different types of dementia are shown (the "split" lanes are from non-adjacent samples on the blot). The box and whisker graphs show median, minimum and maximum values. One way ANOVA with Dunnett's post-hoc test. The RCAN1 measurements for DLB FCX cases (in Panel 2c) were not included due to insufficient numbers. \*p\<0.05.](nihms-1034718-f0002){#F2}

![Levels of ITSN1-L, ITSN1-S and RCAN1 in AD white blood cells.\
Western blotting was performed on homogenates of white blood cells of AD (n=36--50) and HC(n=11-- 20). a, b and c) There were no differences between the groups for the level of ITSN1-L, ITSN1- S and RCAN1. Representative blots are shown. The box and whisker graphs show median, minimum and maximum values.](nihms-1034718-f0003){#F3}

###### 

Demographics for the post-mortem tissues used in this study.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case No.   Age   Sex   Tissue\     Post- mortem   Diagnosis   Cause of death
                         available                              
  ---------- ----- ----- ----------- -------------- ----------- ------------------------------------------------------------------------------------------------------------------------
  40/04      91    F     FCX/TCX     3.8            Control     Unknown

  19/13      87    F     FCX/ TCX    3.83           Control     Respiratory failure

  34/11      91    F     FCX/ TCX    3.33           Control     Unknown

  15/08      82    M     FCX/ TCX    13.5           Control     Unknown

  41/08      91    F     FCX/ TCX    4.82           Control     Pneumonia

  30/04      90    F     FCX/ TCX    3.8            Control     Lung cancer

  05/317     73    M     -/ TCX      49             Control     Ischemic Heart Disease, Coronary Artery Atherosclerosis

  26/05      91    M     FCX/-       4              Control     Pneumonia

  04/104     61    F     FCX/-       71             Control     Acute myocardial infarction, Ischaemic heart disease, Hypertension

  05/975     51    M     FCX/-       64             Control     Asthma in a man with cardiac sarcoid

  03/480     70    M     -/TCX       13.5           AD          Malignant melanoma, Alzheimer's Disease

  03/653     60    M     FCX/TCX     64.5           AD          Acute upper airways obstruction, Impaction of large food bolus, Dementia (from clinical history)

  03/213     80    M     -/ TCX      24             AD          Not available

  04/323     82    M     -/ TCX      25             AD          Heart Attack, Arteriosclerosis, Cerebral Atrophy, Dementia

  04/013     81    M     -/ TCX      23.5           AD          Unknown

  04/164     76    F     -/ TCX      70             AD          Myocardial infarction, Coronary atherosclerosis, Hypertension, Alzheimer's Disease

  04/206     84    M     -/ TCX      73             AD          Faecal Peritonitis, Diverticulitis Carcinoma of Rectum, Abdominal Aortic Aneurysm

  03/711     91    F     -/ TCX      34             AD          Malignant mesothelioma

  24/11      86    M     -/ TCX      2.92           AD          AD

  04/076     83    M     -/ TCX      10             AD          Congestive Cardiac Failure, Generalised Atherosclerosis

  04/042     78    F     -/ TCX      19.5           AD          Unknown

  03/512     65    M     -/ TCX      56.5           AD          Acute myocardial infarction, Coronary artery atherosclerosis, Dilated cardiomyopathy

  04/497     61    M     -/ TCX      13.5           AD          Unknown

  04/410     71    M     -/ TCX      66             AD          Urinary sepsis, Dementia

  05/840     68    M     -/ TCX      15             AD          Alzheimer's disease

  04/618     83    M     -/ TCX      14             AD          Ischemic heart disease

  05/271     83    F     -/ TCX      11.5           AD          Old age, Alzheimer's disease

  05/1055    87    M     -/ TCX      29.5           AD          Ischaemic Heart Disease, Coronary Atherosclerosis

  05/684     88          FCX/ TCX    58             AD          Ruptured abdominal aortic aneurysm, Atherosclerosis, Coronary artery, atherosclerosis

  05/314     89          FCX/ TCX    43.5           AD          Alzheimer's disease , Cancer of bowel 2003

  04/524     84          FCX/ TCX    28.5           AD          Hypostatic Pneumonia complicating recovery following operative repair of a fractured neck of femur sustained in a fall

  05/859     72          -/ TCX      38             AD          Pneumonia −1 week, Dementia of uncertain aetiology - 15 years

  05/546     74          FCX/-       61.5           Non-AD      Coronary Artery Atherosclerosis

  04/556     75          FCX/-       44             Non-AD      Acute on chronic COAD complicating recovery post op \# NOF

  05/751     75          FCX/-       11.5           Non-AD      Heart attack

  05/1117    77          FCX/-       5              Non-AD      Pneumonia, Dementia - microvascular ischemia and Alzheimer's disease

  05/318     71          FCX/-       25             Non-AD      Pulmonary Embolism, Deep Vein Thrombosis, Myocardial Sarcoid, Acute Enterocolitis

  05/728     83          FCX/-       16             Non-AD      Bronchopneumonia, Fractured neck of femur, Dementia, recurrent delirium

  03/923     91    M     FCX/-       48             Non-AD      Complications of surgical correction of fractured neck of femur, General debility, Dementia, Hepatic Abscess, IHD, CRF

  05/665     77    M     FCX/-       31.5           Non-AD      Respiratory Failure, Emphysema, Lung Cancer, COAD, Diabetes, Ischaemic Heart Disease, Hypertension

  03/983     85    M     -/TCX       55             Non-AD      Ischaemic heart disease, Coronary artery atherosclerosis

  04/034     73    F     -/TCX       26.5           Non-AD      Pulmonary embolism, Deep Vein Thrombosis, Diverticular disease

  04/112     73    M     -/ TCX      22             Non-AD      Ischaemic Heart Disease, Coronary Artery Atherosclerosis, Aortic Stenosis

  04/424     75    F     -/ TCX      22.5           Non-AD      Lobar Pneumonia, Coronary Artery Atherosclerosis

  04/250     79    M     -/ TCX      31.5           Non-AD      Metastatic malignant pleural mesothelioma

  03/964     82    M     -/ TCX      50             Non-AD      Unknown

  04/041     82    M     -/ TCX      22             Non-AD      Myocardial infarction

  05/898     85    M     -/ TCX      9              Non-AD      Cardiac failure, Hypertension, Heart disease

  03/514     59    M     -/ TCX      14.5           Non-AD      Progressive supranuclear palsy, Aspiration pneumonia

  05/665     77    M     -/ TCX      31.5           Non-AD      Respiratory Failure, Emphysema, Lung Cancer, COAD, Diabetes, Ischaemic Heart Disease, Hypertension

  05/728     83    F     -/ TCX      16             Non-AD      Bronchopneumonia, Fractured neck of femur, Dementia, recurrent delirium

  04/249     91    F     FCX/        40.5           DLB         Pneumonia

  05/623     87    F     FCX/-       30             DLB         Cardiac arrest - sudden, Ischaemic heart disease --years, Lewy body dementia - many years

  04/171     82    F     FCX/-       54             DLB         Unknown

  04/245     79    M     -/ TCX      20             DLB         Acute renal failure, Senile debility, Dementia with Lewy bodies

  04/157     91    F     -/ TCX      71.5           DLB         Pulmonary Thromboembolism, Thrombosis of left calf

  04/510     73    M     -/ TCX      65             DLB         Unknown

  05/751     75    M     -/ TCX      11.5           DLB         Heart attack
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD: Alzheimer's Disease; Non-AD: Non-Alzheimer's Disease; DLB: Dementia with Lewy Bodies. FCX: Frontal Cortex, TCX; Temporal Cortex.

###### 

Correlation between proteins and metals in AD white blood cells.

                            Metal level          RCAN1                      ITSN1-S                    ITSN1-L
  ------------------------- -------------------- -------------------------- -------------------------- -------------------------
  **AD Iron (μg/g)**        398.3 ± 42.2, n=48   r=0.09 (−.027 to 0.37)     r=−0.18 (−0.48 to 0.15)    r=−0.11 (−0.43 to 0.24)
  **HC Iron (μg/g)**        414.8 ± 88.4, n=17   r=−0.38 (−0.74 to 0.14)    r=−0.23 (−0.73 to 0.43)    r=−0.28 (−0.75 to 0.38)
  **AD Zinc (μg/g)**        176.3 ± 12.1, n=49   r=0.23 (−0.06 to 0.48)     r=0.12 (−0.21 to 0.43)     r=−0.79 (−0.40 to 0.26)
  **HC Zinc (μg/g)**        171.3 ± 21.9, n=19   r=−0.28 (−0.66 to 0.21)    r=−0.22 (−0.72 to 0.44)    r=−0.24 (−0.73 to 0.42)
  **AD Copper (μg/g)**      9.6 ± 0.8, n=47      r=0.22 (−0.08 to 0.48)     r=0.25 (−0.09 to 0.53)     r=0.13 (−0.21 to 0.45)
  **HC Copper (μg/g)**      9.9 ± 1.6, n=19      r=−0.17 (−0.59 to 0.32)    r=−0.22 (−0.73 to 0.43)    r=−0.17 (−0.69 to 0.48)
  **AD Calcium (μg/g)**     3752 ± 265.3, n=47   r=0.11 (−0.19 to 0.39)     r=0.18 (−0.16 to 0.47)     r=0.07 (−0.28 to 0.41)
  **HC Calcium (μg/g)**     3349 ± 323.2, n=18   r=−0.37 (−0.71 to 0.11)    r=−0.21 (−0.72 to 0.45)    r=−0.24 (−0.73 to 0.41)
  **AD Magnesium (μg/g)**   2311 ± 125.8, n=46   r=0.16 (−0.15 to 0.43)     r=0.06 (−0.28 to 0.39)     r=−0.18 (−0.48 to 0.16)
  **HC Magnesium (μg/g)**   2137 ± 208.5, n=18   r=−0.37 (−0.71 to 012)     r=−0.30 (−0.76 to 0.36)    r=−0.35 (−0.79 to 0.31)
  **AD Manganese (μg/g)**   1.1 ± 0.1, n=49      r=0.16 (−0.13 to 0.43)     r=0.11 (−0.23 to 0.42)     r=−0.12 (0.44 to 0.23)
  **HC Manganese (μg/g)**   1.1 ± 0.2, n=19      r=−0.35 (−0.7 to 0.14)     r=−0.16 (−0.69 to 0.48)    r=−0.21 (−0.72 to 0.44)
  **AD Selenium (μg/g)**    2.5 ± 0.2, n=45      r=0.005 (−0.29 to 0.30)    r=0.07 (−0.28 to 0.40)     r=0.05 (−0.32 to 0.40)
  **HC Selenium (μg/g)**    2.8 ± 0.3, n=20      r=0.13 (−0.36 to 0.56)     r=−0.18 (−0.71 to 0.47)    r=−0.19 (−0.71 to 0.46)
  **AD Aluminium (μg/g)**   539.4 ± 47.9, n=46   r=0.08 (−0.22 to 0.37)     r=0.07 (−0.28 to 0.4)      r=−0.13 (−0.46 to 0.22)
  **HC Aluminium (μg/g)**   460.3 ± 68.5, n=18   r=−0.23 (−0.64 to 0.28)    r=−0.25 (−0.74 to 0.41)    r=−0.31 (−0.77 to 0.35)
  **AD Lead (μg/g)**        2.2 ± 0.2, n=46      r=0.17 (−0.13 to 0.45)     r=0.292 (−0.051 to 0.57)   r=0,55 (0.24 to 0.76)
  **HC Lead (μg/g)**        2.9 ± 0.6, n=19      r=−0.056 (−0.51 to 0.42)   r=−0.07 (−0.64 to 0.55)    r=−0.22 (−0.77 to 0.52)

This table shows the level of metals in the white blood cells (μg/g), and Pearson correlation coefficient (r value and 95% confidence interval in the bracket) expressing the correlations between proteins (RCAN1, ITSN1-S and ITSN1-L) and metals in Alzheimer's disease (AD) white blood cells compared with the healthy controls (HC). There are no correlation between any of the proteins and metals. The level of different metals in the WBC was the same between the groups of AD and control samples. A two-tailed Pearson's correlation test was used for statistical analysis.
